T. Rowe Price Associates
AVBP icon

T. Rowe Price Associates’s ArriVent BioPharma AVBP Stock Holding History

T. Rowe Price Associates’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Buy
31,551
+8,958
+40% +$264K ﹤0.01% 2286
2026
Q1 		$522K Buy
22,593
+6,478
+40% +$146K ﹤0.01% 2438
2025
Q4 		$325K Buy
16,115
+1,760
+12% +$36.6K ﹤0.01% 2613
2025
Q3 		$265K Buy
14,355
+2,902
+25% +$57K ﹤0.01% 2665
2025
Q2 		$250K Sell
11,453
-1,018
-8% -$21.1K ﹤0.01% 2610
2025
Q1 		$231K Buy
12,471
+1,506
+14% +$36.9K ﹤0.01% 2573
2024
Q4 		$293K Buy
10,965
+1,620
+17% +$46.5K ﹤0.01% 2521
2024
Q3 		$220K Buy
+9,345
New +$212K ﹤0.01% 2620

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates's AVBP Position: Q2 2026 in Review

T. Rowe Price Associates increased its ArriVent BioPharma (AVBP) stake by 40% in Q2 2026, buying an estimated $264K and bringing the position to 31,551 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.

T. Rowe Price Associates first reported a position in AVBP in Q3 2024 and has held it in 8 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • T. Rowe Price Associates held 31,551 shares of ArriVent BioPharma worth $1.1M as of Q2 2026.
  • T. Rowe Price Associates bought 8,958 ArriVent BioPharma shares in Q2 2026, an estimated $264K.
  • ArriVent BioPharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2286 holding.
  • T. Rowe Price Associates first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 8 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.